Filing identity and reporting period
Important source mismatch: The supplied filing is IsoRay, Inc.’s Form 10-Q, not a filing for Perspective Therapeutics, Inc. It covers the quarter and six months ended December 31, 2015 (the second quarter of IsoRay’s fiscal 2016); it was signed February 9, 2016.
Business context
IsoRay manufactures and sells Cesium-131 brachytherapy seeds, primarily for prostate cancer, and the GliaSite radiation therapy system. Seed sales accounted for 99% of product sales in both the quarter and six-month period. The filing describes international distributors and efforts to expand seed use into other cancer treatments.
Financial performance
| Metric | Three months ended Dec. 31, 2015 | Three months ended Dec. 31, 2014 | Six months ended Dec. 31, 2015 | Six months ended Dec. 31, 2014 |
|---|---|---|---|---|
| Product sales | $1.189 million | $1.066 million | $2.450 million | $2.108 million |
| Gross profit (loss) | $27,000 | $(38,000) | $110,000 | $(93,000) |
| Operating loss | $(1.410) million | $(1.020) million | $(2.501) million | $(2.181) million |
| Net loss applicable to common shareholders | $(1.314) million | $(910,000) | $(2.336) million | $(1.698) million |
| Loss per share, basic and diluted | $(0.02) | $(0.02) | $(0.04) | $(0.03) |
Gross margin was approximately 2% for the quarter and 5% for the six-month period, compared with gross losses in the prior-year periods. Quarterly revenue rose 12% and six-month revenue rose 16%. Seed sales increased, while GliaSite sales fell sharply. G&A expense rose 109% for the quarter and 68% for six months, principally due to securities-litigation legal fees and approximately $300,000 of accrued CEO severance.
Cash, liquidity, and debt
At December 31, 2015, cash and cash equivalents were $679,000; certificates of deposit totaled $17.08 million, of which $5.16 million was classified as non-current. Cash, cash equivalents, and certificates of deposit together totaled $17.76 million. The balance sheet showed total liabilities of $2.19 million, including a $123,000 warrant derivative liability and a $991,000 asset retirement obligation; no interest-bearing debt is shown.
For the six months, operating cash use was $1.92 million, investing cash use was $2.66 million (primarily certificate-of-deposit purchases and maturities), and financing provided $36,000. Cash and cash equivalents decreased by $4.55 million, in part as funds were placed in certificates of deposit. Management estimated monthly required cash operating expenditures at approximately $320,000, versus $293,000 a year earlier. Based on February 5, 2016 balances and assumptions that revenue and expenses remain at current levels, management said available cash and investments should cover anticipated needs for three years.
Material changes, outlook, and risks
- Revenue mix and trends: Prostate seed revenue grew 13% in the quarter and 17% over six months; other seed-treatment revenue also increased. GliaSite revenue declined 44% for the quarter and 69% for six months, with management citing weak adoption and unfavorable currency effects for foreign distributors.
- Costs and losses: Better sales and gross profit did not offset higher operating expenses, especially legal costs and CEO severance. Management cautioned that profitability is not assured; sales had not reached breakeven levels.
- Funding outlook: The three-year liquidity estimate depends on revenue and expenses remaining at current levels. Management said future financing could include equity, strategic collaborations, or debt, and any equity financing could dilute shareholders. Fiscal 2016 manufacturing capital equipment spending was expected to be below $200,000, excluding uncertain future facility construction costs.
- Supply concentration: Cesium-131 sourcing is a significant risk. A Russian supplier shutdown caused a disruption in November 2015; the company said its other source could cover needs only in combination with Russian supply for roughly three to four weeks. The Russian supply agreement was extended through March 31, 2017, but alternative sourcing is not assured.
- Customer concentration: Five customers generated approximately 54% of revenue, and one customer group represented 35% of accounts receivable. Loss of key customers or collection difficulties could materially affect results.
- Legal and other contingencies: A consolidated securities class action remained pending; the company moved to dismiss it, with oral argument scheduled for April 21, 2016. The filing also describes a property purchase completed February 5, 2016 for $168,000, subject to ten-year development and operating covenants; failure to comply could trigger an estimated payment of about $256,000, subject to property valuation.
- Leadership change: CEO and Chairman Dwight Babcock retired effective January 7, 2016. The company accrued approximately $300,000 of severance in the December quarter; Thomas LaVoy was appointed CEO effective February 15, 2016.
Most important facts to verify
- Confirm the intended issuer: this source is IsoRay, Inc., not Perspective Therapeutics, Inc.
- Review revenue growth and gross-margin improvement against continuing operating losses and cash burn.
- Verify the sustainability and maturity schedule of certificates of deposit and the assumptions behind management’s three-year liquidity estimate.
- Assess Cesium-131 supply alternatives, supplier concentration, and the status of supply-contingency testing.
- Monitor customer concentration, securities litigation, severance costs, and compliance with the property development covenants.